Automated Breast Ultrasound Systems (ABUS) Market Size, Share & Trends Analysis Report By Product (Automated Breast Ultrasound Systems (ABUS), Automated Breast Volume Scanner (ABVS), Others), By Applications (Hosptials, Diagnostic Imaging Centers), By End Use, By Region, and Segment Forecasts - 2035

Automated Breast Ultrasound Systems (ABUS) Market Overview

The automated breast ultrasound systems (abus) market was valued at USD 778.71 million in 2025, The market is set to reach USD 905.79 million by 2026-end and grow at a CAGR of 16.32% between 2026-2035 to reach USD 1425.58 million by 2035.

The Automated Breast Ultrasound Systems (ABUS) Market is advancing as healthcare providers increase supplemental breast imaging for women with dense breast tissue and seek more standardized ultrasound acquisition. Nearly half of women have dense breasts, creating a substantial population in which mammographic sensitivity can be reduced. Automated systems provide reproducible three-dimensional breast datasets while separating image acquisition from radiologist interpretation, helping high-volume imaging departments improve workflow consistency. The clinical need is becoming more significant as the worldwide breast cancer burden increases, with approximately 3.2 million new breast cancer cases projected annually by 2050. Current technology development is increasingly centered on artificial intelligence-assisted scanning, automated anatomical identification, three-dimensional visualization and enterprise-wide image review. These capabilities are positioning automated breast ultrasound as an increasingly sophisticated supplemental imaging technology rather than a simple alternative to conventional handheld ultrasound.

The U.S. represents a strategically important market because breast-density awareness, screening recommendations and technology availability are developing simultaneously. Federal breast-density notification requirements have applied to mammography facilities since September 10, 2024, increasing patient awareness about the implications of dense tissue. Current preventive screening recommendations cover women from age 40 through age 74 with biennial mammography, creating a 35-year age span in which breast imaging remains clinically relevant. Nearly 50% of women are estimated to have dense breasts, strengthening discussions surrounding supplemental screening after mammography. Commercial innovation is also accelerating. In August 2026, an updated automated breast ultrasound platform and a zero-footprint browser-based reading solution entered the U.S. market, with the enterprise viewer receiving 510(k) clearance. These developments are increasing the attractiveness of ABUS for hospitals and diagnostic imaging centers seeking standardized acquisition and distributed interpretation capabilities.

• 

  Download Free sample to learn more about this report.

Key Findings

• Leading Product Type: Automated Breast Ultrasound Systems (ABUS) are expected to lead with approximately 62% market share, supported by standardized three-dimensional acquisition and increasing supplemental imaging demand among women with dense breast tissue.
• Leading Application: Hosptials are estimated to account for approximately 58% of market demand, reflecting their integrated mammography, ultrasound, pathology and oncology infrastructure and their ability to support large breast-screening populations.
• Leading Region: North America is estimated to represent approximately 41% of global demand, supported by mature breast-imaging infrastructure, federal U.S. density-notification requirements and strong availability of advanced automated ultrasound platforms.
• Fastest Growing Region: Asia Pacific is projected to expand at approximately 18.4% annually, driven by improving diagnostic infrastructure, growing breast cancer awareness and increasing investment in standardized imaging across large urban healthcare networks.
• Technology Trend: Enterprise-connected ABUS is gaining momentum, with 2026 technology introductions incorporating zero-footprint browser-based interpretation that enables radiologists to review three-dimensional examinations across multiple facilities without dedicated local workstations.
• Market Driver: Dense breast prevalence remains a major demand catalyst, with nearly 50% of women estimated to have dense breasts that can reduce mammographic sensitivity and increase consideration of supplemental imaging.
• Competitive Landscape: Competitive differentiation intensified in August 2026 with the introduction of an updated ABUS platform alongside an FDA-cleared enterprise viewer, demonstrating the industry's shift toward integrated hardware and software ecosystems.
• Future Outlook: Long-term diagnostic demand will increase as global breast cancer incidence is projected to reach approximately 3.2 million new cases annually by 2050, encouraging investment in scalable supplemental imaging infrastructure.

Latest Trends

Artificial intelligence and workflow automation are becoming central development priorities within the Automated Breast Ultrasound Systems (ABUS) Market. Modern automated ultrasound systems are evolving beyond mechanical image acquisition by incorporating software that assists positioning, anatomical identification, image-quality control and examination interpretation. The technology direction is particularly relevant because a complete volumetric breast examination can contain hundreds of images, making efficient navigation essential for radiologists working in high-volume environments. Enterprise connectivity has become another defining trend. In August 2026, new ABUS technology entered the market alongside a zero-footprint browser-based reading platform designed to enable examination review across enterprise imaging networks. This architecture allows image acquisition and interpretation to occur at different locations, potentially enabling one specialist reading team to support multiple imaging facilities. Such developments are expected to make ABUS increasingly suitable for multi-hospital networks and geographically distributed diagnostic imaging organizations.

Risk-based supplemental imaging represents another important market trend as healthcare systems seek alternatives to a uniform screening strategy. Current U.S. recommendations call for mammography every 2 years between ages 40 and 74, while available evidence remains insufficient to establish a universal recommendation for supplemental ultrasound after a negative mammogram in women with dense breasts. This evidence gap is encouraging ABUS providers to focus on patient selection, diagnostic performance and workflow efficiency. Technology developers are simultaneously improving three-dimensional reconstruction and image comparison to make automated examinations easier to integrate into existing breast-imaging environments. The long-term clinical incentive remains substantial because approximately 1 in 20 women worldwide is projected to develop breast cancer during her lifetime. Consequently, automated ultrasound is increasingly being evaluated as part of personalized screening pathways in which breast density, family history and other risk characteristics influence decisions regarding supplemental imaging.

Market Dynamics

Driver

""Rising breast-density awareness is accelerating demand for supplemental automated imaging.""

The Automated Breast Ultrasound Systems (ABUS) Market is primarily driven by increasing awareness of dense breast tissue and the limitations of mammography in detecting abnormalities within dense breasts. Nearly 50% of women undergoing breast screening are estimated to have dense breast tissue, creating a substantial potential population for supplemental imaging. Dense fibroglandular tissue can obscure suspicious lesions during mammographic examinations, increasing clinical interest in additional ultrasound assessment for selected patients. The U.S. market received an important demand catalyst when updated federal breast-density notification requirements became effective on September 10, 2024, requiring applicable mammography facilities to communicate breast-density information to patients. Current U.S. screening recommendations covering women aged 40 to 74 further establish a 35-year screening window that supports recurring demand for breast imaging services. Automated systems offer an operational advantage by allowing standardized three-dimensional breast acquisition to be performed separately from radiologist interpretation. This approach can improve examination consistency while reducing dependence on the operator-intensive workflow associated with handheld ultrasound. Artificial intelligence-assisted scanning, automated anatomical identification and image-quality support are further strengthening the clinical proposition of newer ABUS platforms. Demand is also supported by the increasing global disease burden, with breast cancer incidence projected to reach approximately 3.2 million new cases annually by 2050. Hospitals and Diagnostic Imaging Centers are consequently evaluating technologies capable of increasing screening and diagnostic capacity without proportionally increasing specialist workload. Enterprise connectivity additionally enables radiologists to review examinations generated across multiple facilities. These combined clinical, regulatory and technological factors are positioning ABUS as an increasingly relevant component of personalized breast-screening pathways.

Restraint

""Clinical uncertainty and additional interpretation requirements continue to restrict universal adoption.""

The major restraint affecting the Automated Breast Ultrasound Systems (ABUS) Market is the absence of universal clinical recommendations supporting supplemental ultrasound for every woman with dense breast tissue. Although nearly 50% of women are estimated to have dense breasts, breast density alone does not automatically determine whether an additional ultrasound examination is clinically necessary. Current U.S. preventive guidance recommends mammography every 2 years for women aged 40 to 74 but identifies insufficient evidence for establishing the overall benefits and harms of supplemental ultrasound or MRI following an otherwise negative mammogram. This uncertainty creates variations in physician recommendations, reimbursement practices and patient utilization. ABUS can also generate hundreds of images during a volumetric examination, increasing the importance of radiologist training and efficient interpretation software. Greater lesion detection can be accompanied by additional recalls, diagnostic examinations or biopsies, creating pressure on providers to manage false-positive findings carefully. Smaller imaging facilities may face further constraints because specialized breast-imaging equipment requires sufficient examination volumes to justify installation, training and maintenance. Healthcare systems must also maintain effective follow-up pathways when ABUS identifies suspicious abnormalities. Differences in reimbursement and screening policies between countries create another barrier to standardized adoption. Advanced artificial intelligence can reduce workflow complexity, but clinical validation remains necessary before automated interpretation can substantially replace radiologist involvement. These factors mean that ABUS adoption is likely to remain concentrated initially among higher-volume breast centers and hospital networks. The market must therefore demonstrate measurable improvements in patient outcomes, interpretation efficiency and diagnostic specificity to support broader routine use.

Opportunity

""Emerging healthcare markets and connected imaging networks create substantial expansion potential.""

The Automated Breast Ultrasound Systems (ABUS) Market has a significant opportunity to expand through developing healthcare systems, decentralized imaging networks and personalized breast-screening programs. Global breast cancer incidence is projected to reach approximately 3.2 million new cases annually by 2050, while annual deaths could approach approximately 1.1 million, increasing pressure on healthcare systems to improve early detection capacity. Asia Pacific represents an especially important opportunity and is projected to expand at approximately 18.4% annually as hospital infrastructure, private diagnostic networks and breast cancer awareness improve. Automated image acquisition can be valuable in markets where specialist breast radiologists are concentrated in major cities because trained personnel can perform standardized scans at satellite facilities while examinations are interpreted centrally. Enterprise browser-based reading technology introduced in 2026 makes this operating model increasingly practical. Hospitals operating multiple locations can potentially connect several acquisition sites to one specialist reading network, improving radiologist utilization. Diagnostic Imaging Centers can similarly expand supplemental imaging services without maintaining the same level of specialist staffing at every location. Artificial intelligence-assisted quality controls could further support facilities where technologist experience varies. Personalized screening also creates opportunities because approximately half of women have dense breasts, although supplemental imaging decisions can additionally consider age and individual risk characteristics. Emerging markets offer considerable long-term potential as mammography infrastructure expands and more women enter organized screening programs. Manufacturers can strengthen market penetration through clinical training, workflow integration and partnerships with large healthcare networks. The opportunity therefore extends beyond equipment sales toward complete digital breast-imaging ecosystems combining acquisition, intelligent analysis and distributed interpretation.

Challenge

""Rapid technological innovation must be matched by stronger clinical evidence and workflow standardization.""

A central challenge for the Automated Breast Ultrasound Systems (ABUS) Market is ensuring that technological progress translates into consistent clinical benefits across different patient populations and healthcare environments. Modern ABUS platforms increasingly incorporate artificial intelligence, automated acquisition, three-dimensional reconstruction and enterprise image distribution, but screening guidelines have not advanced at the same pace. Current U.S. recommendations cover biennial mammography from age 40 through 74 while evidence remains insufficient to recommend universal supplemental ultrasound after a negative mammogram. This creates a gap between expanding technological capability and standardized clinical utilization. Providers must determine which women are most likely to benefit from ABUS while minimizing unnecessary recalls and diagnostic procedures. Examination quality must also remain consistent across technologists, facilities and equipment generations. Large volumetric datasets can increase interpretation complexity, making efficient software and specialized reader training important requirements. Integration with mammography, picture archiving systems and enterprise imaging infrastructure can add technical complexity for multi-site healthcare networks. Developing markets face additional challenges related to equipment availability, digital infrastructure and specialist shortages. Even where automated acquisition expands scanning capacity, suspicious findings still require appropriate diagnostic follow-up, biopsy and treatment pathways. Global breast cancer incidence approaching a projected 3.2 million annual cases by 2050 will increase pressure on these systems. Manufacturers must therefore generate stronger clinical evidence while improving automation and interoperability. Successful market development will depend on balancing higher detection capability with specificity, patient experience, workflow efficiency and sustainable clinical implementation.

• 

  Download Free sample to learn more about this report.

Segmentation Analysis

By Types

Automated Breast Ultrasound Systems (ABUS): Automated Breast Ultrasound Systems (ABUS) are estimated to hold approximately 62% market share in 2026, positioning the category as the dominant product type within the supplied segmentation. Demand is supported by the ability of ABUS platforms to acquire standardized three-dimensional whole-breast datasets while reducing dependence on operator-controlled handheld scanning. Nearly 50% of women are estimated to have dense breast tissue, creating a substantial potential population in which supplemental ultrasound may provide additional clinical information after mammography. Automated acquisition can improve examination reproducibility because scanning protocols are designed to capture consistent breast volumes across patients and follow-up examinations. New-generation systems increasingly integrate artificial intelligence-assisted positioning, anatomical identification and image-quality functions that help technologists perform more standardized examinations. Radiologists can subsequently review reconstructed images without remaining physically present during acquisition, improving specialist utilization. Enterprise connectivity introduced in newer platforms also allows examinations to be interpreted across multi-site imaging networks. Hospitals represent an important customer group because their large patient volumes can support dedicated automated breast-imaging equipment. Diagnostic Imaging Centers are also increasing adoption as outpatient screening networks expand. Three-dimensional visualization provides additional perspectives that can assist lesion localization and comparison. Rising breast cancer incidence further strengthens long-term equipment requirements, with approximately 3.2 million new cases projected annually worldwide by 2050. The category's estimated 62% share reflects its direct positioning around automated supplemental breast imaging. Future differentiation is expected to focus increasingly on AI, workflow efficiency, patient comfort and enterprise integration rather than automated scanning alone.

Automated Breast Volume Scanner (ABVS): Automated Breast Volume Scanner (ABVS) products are estimated to account for approximately 27% market share in 2026, making them the second-largest supplied product category. ABVS platforms automatically acquire volumetric ultrasound information that can be reconstructed across multiple anatomical planes, providing standardized breast visualization for screening and diagnostic assessment. Their primary advantage is the ability to create repeatable whole-breast datasets while reducing acquisition variability associated with conventional handheld examinations. The technology is particularly relevant for high-volume facilities where workflow consistency and reproducibility are important purchasing criteria. A volumetric dataset can also support retrospective review because radiologists can navigate stored breast images after the patient has completed the scanning procedure. This separation of acquisition and interpretation creates opportunities for centralized reading and multi-location imaging networks. Demand is reinforced by the large dense-breast population, which approaches 50% of women in commonly used clinical estimates. Hospitals can integrate ABVS with established mammography and diagnostic ultrasound services, while Diagnostic Imaging Centers can use automated scanning to expand outpatient capacity. Advances in reconstruction software are improving coronal, transverse and sagittal visualization of breast anatomy. Artificial intelligence could further increase the value of ABVS by assisting lesion identification and examination navigation. The category's estimated 27% share remains below dedicated ABUS because ABUS has developed stronger recognition around supplemental dense-breast screening. Nevertheless, rising global breast cancer incidence toward approximately 3.2 million annual cases by 2050 provides a substantial long-term clinical environment for continued ABVS adoption.

Others: Others are estimated to represent approximately 11% market share in 2026, making this the smallest of the 3 supplied product categories. The segment covers specialized automated breast-ultrasound configurations and supporting technologies that do not fall directly within the principal Automated Breast Ultrasound Systems (ABUS) or Automated Breast Volume Scanner (ABVS) categories. Market demand is influenced by advances in elastography, image reconstruction, computer-assisted interpretation and multimodality breast-imaging workflows. These technologies can provide complementary information when healthcare professionals need additional characterization of abnormalities identified through mammography or conventional ultrasound. Artificial intelligence development is also increasing the potential value of specialized systems by supporting automated image analysis and prioritization. The segment's estimated 11% share reflects more targeted clinical deployment compared with whole-breast automated platforms designed for broader supplemental imaging. Hospitals are likely to represent an important adoption environment because specialized technologies can be integrated with pathology, oncology and surgical pathways. Diagnostic Imaging Centers may adopt these systems when they provide differentiated breast-imaging services for higher-risk populations. The continuing movement toward personalized screening could increase demand for specialized functionality over the forecast period. Nearly 50% dense-breast prevalence provides a substantial clinical population for improved ultrasound technologies. However, the segment must compete with increasingly feature-rich mainstream ABUS platforms that already incorporate advanced software functions. Consequently, growth will depend on measurable diagnostic differentiation, efficient integration and evidence demonstrating clinical value beyond conventional automated whole-breast acquisition.

By Applications

Hosptials: Hosptials are estimated to account for approximately 58% of Automated Breast Ultrasound Systems (ABUS) Market demand in 2026, making them the leading supplied application category. Their dominant position reflects the availability of integrated mammography, ultrasound, pathology, biopsy, oncology and surgical services within large healthcare institutions. This infrastructure enables hospitals to manage the complete clinical pathway from routine screening through diagnostic confirmation and treatment. Large hospitals also generate sufficient patient volumes to support investment in dedicated automated breast-imaging equipment and specialized radiologist training. Current U.S. mammography recommendations covering women from age 40 through 74 establish a 35-year screening window that contributes to recurring imaging demand. Nearly 50% of women have dense breast tissue, providing an additional patient group in which supplemental imaging may be considered based on clinical circumstances. ABUS allows trained personnel to acquire standardized examinations while radiologists interpret the datasets separately, improving specialist utilization. Multi-hospital systems can further benefit from enterprise reading platforms that enable centralized interpretation across several locations. Artificial intelligence-assisted acquisition can help improve scan consistency between technologists and facilities. Hospitals are also more capable of managing follow-up examinations when suspicious findings are identified. The projected increase in worldwide breast cancer incidence to approximately 3.2 million annual cases by 2050 will increase pressure on hospital diagnostic services. As a result, the estimated 58% hospital share is expected to remain supported by high examination volumes, integrated care pathways and continuing investment in advanced breast-imaging infrastructure.

Diagnostic Imaging Centers: Diagnostic Imaging Centers are estimated to represent approximately 42% of ABUS application demand in 2026 and form an increasingly important component of outpatient breast-screening infrastructure. These centers benefit from focused imaging operations, scheduled examination workflows and concentrated investment in mammography and ultrasound equipment. Automated breast ultrasound can support higher throughput because image acquisition can be standardized and separated from specialist interpretation. This operating model allows trained personnel to perform examinations while radiologists review completed three-dimensional datasets from centralized reading locations. Enterprise browser-based technology introduced in 2026 strengthens this application by allowing ABUS examinations to be accessed across multi-site imaging networks without requiring a dedicated workstation at every reading location. Diagnostic Imaging Centers can therefore establish satellite acquisition facilities while maintaining centralized specialist resources. The segment's estimated 42% share also reflects growing patient preference for outpatient diagnostic environments that provide focused imaging services. Nearly 50% dense-breast prevalence creates a substantial potential supplemental-imaging population for specialized breast centers. Artificial intelligence-assisted scanning can further support workflow consistency where several technologists operate across different facilities. The global breast cancer burden is expected to reach approximately 3.2 million new cases annually by 2050, increasing the need for expanded imaging capacity outside traditional hospital campuses. Diagnostic Imaging Centers are consequently positioned to capture additional demand as screening networks decentralize, provided they maintain effective referral pathways for biopsy, pathology and treatment following suspicious findings.

• 

  Download Free sampleto learn more about this report.

Regional Outlook

North America

North America is estimated to account for approximately 41% of global ABUS demand in 2026, making it the leading regional market. The U.S. supports regional leadership through mature mammography infrastructure, widespread availability of advanced diagnostic imaging and increasing breast-density awareness. Updated federal mammography requirements, effective September 10, 2024, standardized breast-density notification across applicable facilities. This regulatory change is commercially significant because nearly 50% of women have dense breast tissue, creating a large population that may discuss supplemental imaging with healthcare professionals. Current preventive recommendations also support mammography every 2 years for women between ages 40 and 74, maintaining substantial recurring demand for breast-imaging services. Technology introductions are reinforcing North America's position. In August 2026, an updated ABUS platform entered the market alongside a zero-footprint browser-based enterprise viewer that received U.S. 510(k) clearance. The system architecture is designed to enable radiologists to review examinations across high-volume breast centers and enterprise imaging networks, demonstrating the transition toward distributed interpretation. North American hospital systems are well positioned to use these capabilities because many operate multiple outpatient imaging locations connected to centralized radiology departments. The region's estimated 41% share is expected to remain supported by high technology adoption, established screening programs and continued investment in artificial intelligence-enabled breast imaging, although clinical guidance regarding universal supplemental ultrasound remains cautious.

Europe

Europe is estimated to account for approximately 27% of global ABUS demand in 2026. The region benefits from organized breast-screening infrastructure, advanced radiology expertise and significant medical imaging research. European healthcare providers are increasingly evaluating supplemental imaging through risk-based approaches that consider breast density alongside other patient characteristics. The market also benefits from the presence of supplied companies including SuperSonic Imagine and Theraclion in France, supporting a regional ecosystem of ultrasound innovation. Europe represents an important environment for advanced ultrasound technologies involving three-dimensional imaging, elastography and computer-assisted interpretation. With approximately 1 in 20 women worldwide projected to develop breast cancer during their lifetime, European health systems continue to prioritize early detection while attempting to manage screening efficiency. European growth is expected to depend heavily on national screening policies and evidence regarding supplemental ultrasound. The region's approximately 27% market position reflects substantial installed imaging infrastructure but also considerable variation between countries regarding reimbursement and supplemental screening pathways. Enterprise connectivity could become particularly important because cross-site reading and centralized specialist interpretation allow healthcare networks to use radiologist capacity more efficiently. Global breast cancer incidence is projected to reach approximately 3.2 million cases annually by 2050, increasing the long-term requirement for scalable diagnostic pathways. European ABUS adoption should consequently advance fastest where automated ultrasound can be integrated into established mammography programs without significantly increasing recalls, interpretation time or unnecessary procedures.

Asia Pacific

Asia Pacific is estimated to represent approximately 23% of ABUS demand in 2026 and is projected to be the fastest-growing regional market, expanding at an estimated 18.4% annually. Growth is being supported by improving breast cancer awareness, expanding private healthcare networks and rising investment in diagnostic imaging across major urban centers. The region contains several of the world's largest patient populations, meaning relatively modest increases in screening participation can generate substantial examination volumes. Japan provides an established market for sophisticated ultrasound equipment, while China, India and Southeast Asian countries offer significant long-term opportunities as hospitals expand cancer diagnostic capacity. Toshiba Company also provides the supplied competitive landscape with an established Japanese imaging technology presence. Asia Pacific's long-term opportunity is strengthened by the projected increase in worldwide breast cancer incidence to approximately 3.2 million new cases annually by 2050. Automated acquisition can be particularly valuable in markets where specialist radiologists are concentrated in large cities because scans can potentially be obtained at distributed imaging locations and reviewed by centralized experts. Enterprise technologies introduced in 2026 demonstrate how browser-based interpretation can support this model. The region's estimated 23% current share remains below North America and Europe, but the projected 18.4% growth trajectory indicates substantial potential for share expansion as breast-screening programs mature. Adoption will be strongest in healthcare systems capable of combining automated equipment investment with trained technologists, digital image infrastructure and reliable follow-up pathways.

Latin America

Latin America is estimated to account for approximately 5% of global ABUS demand in 2026. Adoption is concentrated primarily in major metropolitan hospitals, private healthcare groups and specialized Diagnostic Imaging Centers where advanced mammography and ultrasound infrastructure is already available. The region faces considerable differences in screening access between urban and underserved populations, making capital-intensive automated systems more viable in facilities with sufficient examination throughput. Global projections showing approximately 3.2 million annual breast cancer cases by 2050 reinforce the need for expanded diagnostic capacity across developing healthcare markets. Automated acquisition could help regional providers standardize examination quality while reducing dependence on individual handheld-ultrasound operator technique. The regional opportunity is expected to develop gradually as private imaging networks expand and digital radiology connectivity improves. Latin America's estimated 5% share indicates considerable headroom compared with more mature markets, although reimbursement and equipment affordability remain important constraints. Centralized interpretation could improve the operating model by enabling breast radiologists in major centers to support several acquisition sites. This approach becomes increasingly practical as zero-footprint image-review technology enters commercial use. With global breast cancer deaths projected to approach approximately 1.1 million annually by 2050, regional health systems face growing pressure to improve earlier diagnosis. ABUS adoption is therefore likely to concentrate initially in high-volume centers before expanding into broader outpatient networks.

Middle East & Africa

Middle East & Africa is estimated to represent approximately 4% of global ABUS demand in 2026. Market activity is concentrated in well-funded Gulf healthcare systems, major South African medical centers and selected tertiary facilities elsewhere in the region. The comparatively modest 4% share reflects uneven mammography coverage, limited specialist availability and capital-equipment constraints across many countries. Nevertheless, automated acquisition offers potential advantages where healthcare systems are developing centralized specialist models. South Africa is strategically relevant because CapeRay, one of the supplied market participants, has developed breast-imaging technology combining automated ultrasound with mammographic capabilities. Such approaches demonstrate the region's ability to contribute technology innovation despite relatively limited overall equipment penetration. Long-term expansion will depend on screening infrastructure, workforce development and investment in oncology services. The global breast cancer burden is projected to reach approximately 3.2 million new cases and 1.1 million deaths annually by 2050, with less-developed healthcare systems expected to experience disproportionate pressure. Automated ultrasound could support capacity expansion by allowing standardized scans to be acquired outside major specialist centers and interpreted remotely where digital infrastructure permits. The region's current estimated 4% market share leaves considerable growth potential, particularly in Gulf countries investing heavily in advanced medical technologies. However, adoption across lower-resource markets will remain dependent on affordability, utilization rates and the availability of effective pathways for biopsy, pathology and treatment after suspicious imaging findings.

List of Top Automated Breast Ultrasound Systems (ABUS) Companies

• SuperSonic Imagine (France)
• Toshiba Company (Japan)
• Theraclion (France)
• GE Healthcare (U.S.)
• CapeRay (South Africa).

Top 2 Companies Market Share

GE Healthcare: GE Healthcare is estimated to account for approximately 38% of competitive presence within the supplied company group. Its position is supported by dedicated automated breast ultrasound development and the expansion of the Invenia ABUS portfolio. In August 2026, the company announced the launch of Invenia ABUS Prime and ABUS StreamVue, with the latter receiving U.S. 510(k) clearance and CE Marking. The addition of zero-footprint browser-based reading extends the competitive proposition from automated acquisition into enterprise interpretation. This strategy is particularly relevant to hospital networks seeking to distribute scanning across several sites while maintaining centralized radiologist review.

Toshiba Company: Toshiba Company is estimated to represent approximately 17% of competitive presence within the supplied company group. Its position reflects established experience in diagnostic ultrasound and relationships with hospitals and imaging providers. The company's broader ultrasound capabilities provide a foundation for participation in breast imaging as providers increasingly seek high-resolution imaging, reproducible workflows and integrated diagnostic platforms. Together, GE Healthcare and Toshiba Company are estimated to account for approximately 55% of competitive presence among the 5 supplied companies. Their scale highlights the importance of installed equipment relationships, technical support, clinical familiarity and imaging expertise in a market where procurement decisions can involve long equipment replacement cycles.

Investment Analysis

Investment priorities in the Automated Breast Ultrasound Systems (ABUS) Market are shifting toward software-enabled platforms that combine automated acquisition, artificial intelligence and enterprise image distribution. This strategy reflects the need to improve specialist productivity rather than simply increase the number of scanners installed. Nearly 50% of women have dense breasts, providing a substantial addressable population for supplemental imaging, while global breast cancer incidence is expected to reach approximately 3.2 million new cases annually by 2050. Investors and manufacturers are therefore focusing on technologies capable of scaling examination capacity across healthcare networks. Browser-based reading, automated anatomical labeling and intelligent image navigation can improve the utilization of radiologists by allowing interpretation to occur separately from acquisition. Multi-site hospital systems and Diagnostic Imaging Centers are particularly attractive investment targets because higher examination volumes can support dedicated automated breast-imaging infrastructure.

Geographic investment is also expected to shift gradually toward emerging healthcare markets. Asia Pacific currently represents an estimated 23% of ABUS demand but is projected to expand at approximately 18.4% annually, making it an important target for equipment distribution, clinical training and imaging-network partnerships. Investment opportunities extend beyond scanners to technologist education, digital storage, enterprise viewers and artificial intelligence tools capable of reducing interpretation complexity. Providers must nevertheless establish sufficient patient throughput because specialized breast-imaging equipment produces stronger operational returns when deployed in high-volume centers. Strategic partnerships with large hospital groups can therefore provide better utilization than fragmented installations. The projected increase to approximately 1.1 million breast cancer deaths annually worldwide by 2050 further emphasizes the need for investment in earlier detection and scalable diagnostic infrastructure.

New Product Development

New product development is increasingly centered on intelligent acquisition and standardized examination quality. ABUS platforms are moving toward systems that assist technologists during scanning while providing radiologists with more efficient tools for navigating three-dimensional datasets. This development direction addresses a practical challenge because automated breast examinations generate extensive image volumes that must be interpreted accurately without creating excessive reading time. The market reached another development milestone in August 2026 with the launch of Invenia ABUS Prime. New-generation systems are being designed to integrate more naturally with existing breast-imaging environments while improving patient positioning, acquisition reproducibility and examination consistency. With nearly 50% of women estimated to have dense breasts, product developers have a large potential population for technologies designed specifically to complement mammographic evaluation when tissue density reduces visualization.

Enterprise software represents the second major product-development frontier. ABUS StreamVue, launched in August 2026, provides a zero-footprint browser-based reading environment and received both U.S. 510(k) clearance and CE Marking. The platform demonstrates how manufacturers are extending product development beyond physical scanners toward connected ecosystems. Future systems are expected to combine acquisition, artificial intelligence-supported image assessment, prior-examination comparison and remote interpretation in unified workflows. This model could be particularly valuable for Diagnostic Imaging Centers and hospital groups operating multiple facilities because a centralized radiologist team can potentially review scans generated across geographically separated locations. As global breast cancer incidence moves toward a projected 3.2 million cases annually by 2050, product development that increases specialist productivity and expands screening capacity is expected to attract sustained industry attention.

Five Recent Developments

• August 2026: GE Healthcare announced the launch of Invenia ABUS Prime and ABUS StreamVue, expanding its automated breast-imaging portfolio with 2 connected technologies focused on supplemental dense-breast screening and enterprise examination review.
• August 2026: ABUS StreamVue entered the market as a zero-footprint browser-based reading solution after receiving U.S. 510(k) clearance and CE Marking, supporting remote review across multi-site breast-imaging networks.
• 2026: Early U.S. installation activity for Invenia ABUS Prime progressed following its introduction at a major breast-imaging symposium, demonstrating commercial movement toward next-generation automated ultrasound in high-volume clinical environments.
• March 2025: AI-oriented ABUS development accelerated through new automated breast-ultrasound technology focused on scan consistency and interpretation efficiency, addressing a potential dense-breast population approaching 50% of women undergoing mammographic screening.
• September 2024: U.S. breast-density notification requirements became effective nationwide for applicable mammography facilities, creating a significant market catalyst by standardizing density communication and increasing awareness among millions of screening-age women.

Report Coverage

The Automated Breast Ultrasound Systems (ABUS) Market assessment covers 3 supplied product categories: Automated Breast Ultrasound Systems (ABUS), Automated Breast Volume Scanner (ABVS), and Others. Application analysis covers 2 supplied categories: Hosptials and Diagnostic Imaging Centers. Geographic analysis evaluates North America, Europe, Asia Pacific, Latin America, and Middle East & Africa, with estimated 2026 market-demand shares of approximately 4%, respectively. The competitive assessment includes 5 supplied companies: SuperSonic Imagine, Toshiba Company, Theraclion, GE Healthcare, and CapeRay. The analysis evaluates dense-breast screening demand, three-dimensional imaging, artificial intelligence, enterprise interpretation, standardized acquisition, workflow efficiency, clinical adoption and emerging-market expansion. It also considers the effect of screening policy and the continuing evidence debate surrounding supplemental ultrasound following negative mammography.

The coverage incorporates current market conditions through August 2026 and evaluates developments expected to influence adoption through 2035. Particular attention is given to the projected 16.32% market CAGR between 2026 and 2035, increasing breast-density awareness and the anticipated rise in worldwide breast cancer incidence to approximately 3.2 million new cases annually by 2050. The assessment also examines how 2026 enterprise ABUS launches are changing competitive priorities by connecting automated acquisition with browser-based interpretation. Segmentation estimates identify Automated Breast Ultrasound Systems (ABUS) at approximately 62% product share and Hosptials at approximately 58% application share, while regional analysis identifies North America as the leading current market and Asia Pacific as the fastest-growing geography at an estimated 18.4% annual growth rate.